Genmab — Maj 2020
-
ASCO
@ASCO
·
35 min
#ASCO20: We're aware of slow loading times on the website due to extremely high traffic. We're working to promptly resolve. Thanks for your patience! -
Initial abstracts were a bit better..
-
chosen dose for phase II 48mg
-
DLBCL complete response 21.4%, was 44% in initial abstracts
-
at data cut there was only treatment with 12mg, there is room for big improvement because chosen dose for phase II is 48mg
-
Måske en fuser?
-
Forventningens glæde er nogen gange den største..;-)
-
-
Næh...kursen...
-
Data er åbenbart ikke gode nok...hypen er ligesom forduftet.
-
De resultater der vises her er med mindre doser end den valgte fase 2 dose på 48 mg
-
Hvis de store har rebalanceret sig her sidst på måneden, så køber de sig jo nok ikke yderligere ind, før måske i næste måned.
-
48 mg kan øge effekten
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind